Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Phytocannabinoids, particularly cannabidiol (CBD), are supported by substantial scientific evidence for the treatment of certain forms of epilepsy. While "phytocannabinoid (unspecified)" could refer to a range of plant-derived cannabinoids, most research and clinical use focus on CBD. Randomized, double-blind, placebo-controlled trials have demonstrated that CBD significantly reduces seizure frequency in patients with treatment-resistant epilepsy, especially Dravet syndrome and Lennox-Gastaut syndrome. These findings led to the FDA approval of Epidiolex, a purified CBD extract, for these indications.

Evidence for other phytocannabinoids (such as THC) in epilepsy is limited and less robust, with some preclinical data but concerns over psychoactive side effects and potential exacerbation of seizures in some cases. Historical and anecdotal use of cannabis for seizures exists, but modern medical validation centers on CBD. Overall, the use of phytocannabinoids—when specifying CBD—is scientifically validated for certain types of severe, refractory childhood epilepsy, with ongoing research into broader applications.

More about Phytocannabinoid (unspecified)
More about Epilepsy

Other ingredients used for Epilepsy

Other health conditions supported by Phytocannabinoid (unspecified)

Products containing Phytocannabinoid (unspecified)